JERUSALEM, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that, as the global market leader in generic pharmaceuticals, Teva is constantly evaluating opportunities to maximize shareholder value, including looking at potential acquisitions. Teva's long-held practice is to only pursue transactions that fit our long-term strategy of delivering profitable growth and enhancing our global leadership position while meeting our stringent financial criteria. While Merck’s generics business would have been a strategic fit for Teva, the terms of this opportunity did not fully meet our investment criteria.
